AI Article Synopsis
- - Researchers investigated the connection between anti-inflammatory drugs (methotrexate and sulfasalazine) and dementia risk in patients over 50 with rheumatoid arthritis.
- - The study found that prior use of methotrexate was linked to a lower risk of developing dementia, especially in those using it for over 4 years; however, no significant association was found with sulfasalazine.
- - The authors concluded that more research is necessary to better understand how methotrexate usage and treatment duration may affect dementia risk.
Article Abstract
Background: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk.
Methods: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia.
Results: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57-1.37).
Conclusions: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137292 | PMC |
| http://dx.doi.org/10.1186/s13195-020-00606-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!